Key Stats for REGN Stock
- 6-Month Performance: 39%
- 52-Week Range: $476 to $821
- Valuation Model Target Price: $999
- Implied Upside: 26%
Value your favorite stocks like Regeneron Pharmaceuticals with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Regeneron Pharmaceuticals stock is up about 39% over the past six months, recently trading near $780 per share, as investors reacted to accelerating Dupixent growth, strong EYLEA HD uptake, and expanding pipeline visibility heading into 2026.
Shares remain just below their $821 52 week high, reflecting sustained institutional demand rather than short-term speculation.
The rally gained momentum after Regeneron delivered a clear fourth quarter earnings beat and reinforced confidence in 2026 growth.
The company reported $3.88 billion in revenue versus $3.76 billion expected and EPS of $11.44 versus $10.74 expected, while global Dupixent sales surged 32% to $4.9 billion, EYLEA HD U.S. sales jumped 66% to $506 million, and LIBTAYO grew 13% to $425 million.
CEO Leonard Schleifer said the company “capped 2025 with another solid quarter of commercial execution,” and management guided 2026 R&D spending to $5.9 billion to $6.1 billion with expectations for at least four FDA approvals over the next year, reinforcing visibility into near-term catalysts.
Regulatory momentum further strengthened the story. Dupixent received an FDA label expansion and a positive EMA pediatric recommendation, expanding its addressable population across immunology indications.
The company also raised its quarterly dividend to $0.94 per share, signaling confidence in free cash flow durability and capital return capacity heading into 2026.
Institutional activity has supported the advance. Harvest Portfolios increased its stake 8.6% to 107,547 shares valued at $60.47 million, Handelsbanken Fonder raised its position 24.8% to 63,049 shares worth $35.45 million, and American Century boosted its holdings 3.8% to 660,595 shares valued at $371.4 million.
Mitsubishi UFJ Asset Management, TD Asset Management, and Banco Santander also added exposure, while Rafferty Asset Management trimmed its stake 11.7% and Director Huda Zoghbi sold 1,638 shares at $781.33.
Institutional investors now own about 83.31% of the company, underscoring continued large holder conviction despite selective trimming.
See analysts’ growth forecasts and price targets for Regeneron Pharmaceuticals (It’s free) >>>
Is REGN Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 9.1%
- Operating Margins: 37%
- Exit P/E Multiple: 15.5x
Revenue is projected to rise from about $14.3 billion in 2025 to roughly $21.0 billion by 2030, supported primarily by continued Dupixent penetration across asthma, atopic dermatitis, COPD, and new immunology indications.
The key driver is mix. High-margin immunology revenue increasingly offsets ophthalmology pricing pressure, allowing earnings growth to outpace revenue growth if indication expansion continues.
Operating margins near 37% assume sustained leverage from Dupixent and improving contribution from oncology assets such as LIBTAYO and other late-stage pipeline programs.
Continued EYLEA HD conversion and regulatory expansion support earnings durability, while at least four expected FDA approvals over the next year could add incremental revenue streams that are not yet fully reflected in forward multiples.
At around $780 per share, the valuation framework implies a target price of $999, representing about 26% total upside in 2026.
That suggests the stock remains moderately undervalued, provided Dupixent maintains double-digit growth and pipeline execution continues.
Performance this year will likely hinge on Dupixent label expansions, oncology readouts, EYLEA HD adoption trends, and operating margin stability above 35%.
Sustained high-margin mix expansion combined with regulatory milestones could support continued earnings momentum, positioning Regeneron for further upside if execution remains consistent.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does REGN Stock Have From Here?
Investors can estimate Regeneron Pharmaceuticals potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See Regeneron Pharmaceuticals true value, or any stock’s, in under 60 seconds (Free with TIKR) >>>
